SLC5A2 and type 2 diabetes mellitus: These datasets were obtained from the following sources: (1) an experimental mouse model of immune-mediated kidney disease (34 markers at 80 nm per pixel); (2) clinical biopsy samples from individuals diagnosed with advanced diabetic kidney disease (DKD) (61 markers at 160 nm per pixel); and (3) research biopsy samples from individuals diagnosed with youth-onset type 2 diabetes (T2D) (142 markers at 80 nm per pixel) without pathological signs of DKD, including a subset of individuals with short-term treatment with SGLT2 inhibitors.